Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna to Present at Upcoming Investor Conferences in September

GlobeNewswire September 9, 2020

Medicenna to Commence Trading on Nasdaq

GlobeNewswire August 20, 2020

Medicenna Reports First Quarter Fiscal 2021 Financial Results and Operational Highlights

GlobeNewswire August 4, 2020

Medicenna to Present at Raymond James Human Healthcare Innovation Conference

Canada NewsWire June 11, 2020

47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

ACCESS Newswire June 3, 2020

Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020

Canada NewsWire May 29, 2020

Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020

Canada NewsWire May 29, 2020

Medicenna Announces March 31, 2020 Year-End Results

Canada NewsWire May 15, 2020

Medicenna Announces Upcoming Presentations at the ASCO Annual Meeting

PR Newswire May 4, 2020

Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public Offering

Canada NewsWire April 15, 2020

Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study

PR Newswire March 25, 2020

Medicenna Announces Closing of Public Offering of $35 Million

Canada NewsWire March 17, 2020

Medicenna Announces Intention to File Final Short Form Prospectus

Canada NewsWire March 12, 2020

IIROC Trade Resumption - MDNA

Canada NewsWire March 4, 2020

Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common Shares

Canada NewsWire March 4, 2020

IIROC Trading Halt - MDNA

Canada NewsWire March 3, 2020

Medicenna Announces Overnight Marketed Offering of Common Shares

Canada NewsWire March 3, 2020

Medicenna Reports Third Quarter Fiscal 2020 Financial Results

Canada NewsWire February 13, 2020

President and CEO of Medicenna Therapeutics Corp., Dr. Fahar Merchant, is Featured on The Stock Day Podcast

Newsfile January 21, 2020

Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm

PR Newswire January 13, 2020